TABLE III

Comparison of Test Results of R&D Studies with Validation Studies

Antibody	Development Stage	Resin Type^{^a}	RVLP LRV (R&D) qPCR	Type of Experiment	w) TCID₅₀
Standard Antibody
A	Early	MM AEX	1.99	Process Optimization	1.02 ≥5.06
A	Early	MM AEX	4.48	Process Optimization	1.02 ≥5.06
New-Format Antibodies
C	Early	MM AEX	1.24	Process optimization	− ≥5.78 ≥0.56 ≥6.42
		MM AEX	≥3.31	Process optimization
		AEX	1.08	Process optimization
		AEX	≥5.54	Process optimization
D	Early	CEX	4.13	Prevalidation/Confirmation	≥5.72
E	Late	MM AEX	4.55	Prevalidation/Confirmation	≥6.13

↵a AEX = anion exchange chromatography, MM AEX = multimodal anion exchange chromatography.